PL3346995T3 - Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności - Google Patents

Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Info

Publication number
PL3346995T3
PL3346995T3 PL16798063T PL16798063T PL3346995T3 PL 3346995 T3 PL3346995 T3 PL 3346995T3 PL 16798063 T PL16798063 T PL 16798063T PL 16798063 T PL16798063 T PL 16798063T PL 3346995 T3 PL3346995 T3 PL 3346995T3
Authority
PL
Poland
Prior art keywords
treatment
immunodeficiency virus
human immunodeficiency
therapeutic compositions
therapeutic
Prior art date
Application number
PL16798063T
Other languages
English (en)
Inventor
Lei Hong
Benjamin Micah Collman
Joanna M. Koziara
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57346085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3346995(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3346995T3 publication Critical patent/PL3346995T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16798063T 2015-11-09 2016-11-08 Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności PL3346995T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562253042P 2015-11-09 2015-11-09
US201662399999P 2016-09-26 2016-09-26
EP16798063.0A EP3346995B1 (en) 2015-11-09 2016-11-08 Therapeutic compositions for treatment of human immunodeficiency virus
PCT/US2016/060989 WO2017083304A1 (en) 2015-11-09 2016-11-08 Therapeutic compositions for treatment of human immunodeficiency virus

Publications (1)

Publication Number Publication Date
PL3346995T3 true PL3346995T3 (pl) 2020-03-31

Family

ID=57346085

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16798063T PL3346995T3 (pl) 2015-11-09 2016-11-08 Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności

Country Status (27)

Country Link
US (4) US10548846B2 (pl)
EP (2) EP3632415A1 (pl)
JP (1) JP6621933B2 (pl)
KR (4) KR102606625B1 (pl)
CN (2) CN113546052A (pl)
AU (2) AU2016354007C9 (pl)
BR (1) BR102016026127A2 (pl)
CA (1) CA2948021C (pl)
CL (1) CL2018001199A1 (pl)
CO (1) CO2018004776A2 (pl)
CR (1) CR20180253A (pl)
EA (1) EA201890654A1 (pl)
EC (1) ECSP18033723A (pl)
ES (1) ES2757560T3 (pl)
IL (1) IL258459A (pl)
MX (1) MX2018005729A (pl)
NZ (1) NZ741957A (pl)
PE (1) PE20181207A1 (pl)
PH (1) PH12018501001A1 (pl)
PL (1) PL3346995T3 (pl)
PT (1) PT3346995T (pl)
SG (1) SG11201802983TA (pl)
SI (1) SI3346995T1 (pl)
SV (1) SV2018005682A (pl)
TW (2) TW202220660A (pl)
UY (1) UY36981A (pl)
WO (1) WO2017083304A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (pl) 2014-06-20 2018-06-23
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3664895A4 (en) 2017-08-09 2021-06-30 VIIV Healthcare Company COMBINATIONS AS WELL AS USES AND TREATMENTS THEREOF
EP3664896A4 (en) * 2017-08-09 2021-06-09 VIIV Healthcare Company COMBINATIONS, USES AND CORRESPONDING TREATMENTS
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
US20210393631A1 (en) * 2018-09-19 2021-12-23 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法
CN117653634A (zh) * 2022-08-24 2024-03-08 安徽贝克制药股份有限公司 包含恩曲他滨、替诺福韦和比克替拉韦的药物组合物
CN119174736A (zh) * 2024-09-09 2024-12-24 安徽贝克生物制药有限公司 一种三联复方片及制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1331208A (zh) 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2004024078A2 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070219243A1 (en) 2005-12-30 2007-09-20 Kearney Brian P Method for improving the pharmacokinetics of HIV integrase inhibitors
WO2008043829A2 (en) 2006-10-14 2008-04-17 Boehringer Ingelheim International Gmbh Method for treating hiv-1 infection by the combined administration of nevirapine, tenofovir and emtricitabine
PL2393485T3 (pl) 2009-02-06 2015-12-31 Gilead Sciences Inc Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
AP3639A (en) 2011-08-16 2016-03-13 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
WO2013116730A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (pl) * 2013-07-12 2018-07-21
EA201690146A1 (ru) 2013-08-14 2016-07-29 Ратиофарм Гмбх Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (pl) * 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
EP4233846B1 (en) 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
KR102100436B1 (ko) 2018-10-30 2020-04-13 울산과학기술원 강자성 원소 치환형 상온 다강성 물질 및 그 제조 방법

Also Published As

Publication number Publication date
TW201726139A (zh) 2017-08-01
KR102606625B1 (ko) 2023-11-27
EP3632415A1 (en) 2020-04-08
ECSP18033723A (es) 2018-05-31
PE20181207A1 (es) 2018-07-23
KR20230015512A (ko) 2023-01-31
CN113546052A (zh) 2021-10-26
MX2018005729A (es) 2018-08-09
US12594244B2 (en) 2026-04-07
WO2017083304A8 (en) 2018-04-19
CN108348473A (zh) 2018-07-31
CR20180253A (es) 2018-07-16
CO2018004776A2 (es) 2018-06-20
AU2016354007A1 (en) 2018-05-10
IL258459A (en) 2018-05-31
UY36981A (es) 2017-06-30
ES2757560T3 (es) 2020-04-29
US11744802B2 (en) 2023-09-05
AU2016354007C1 (en) 2020-09-10
JP6621933B2 (ja) 2019-12-18
KR20180067702A (ko) 2018-06-20
TW202220660A (zh) 2022-06-01
US20210052502A1 (en) 2021-02-25
US20220378798A1 (en) 2022-12-01
US20260027061A1 (en) 2026-01-29
AU2020200995B2 (en) 2022-04-07
US10548846B2 (en) 2020-02-04
JP2018532811A (ja) 2018-11-08
EP3346995B1 (en) 2019-08-28
HK1256903A1 (en) 2019-10-04
HK1256093A1 (zh) 2019-09-13
AU2020200995A1 (en) 2020-02-27
CA2948021A1 (en) 2017-05-09
BR102016026127A2 (pt) 2017-05-16
CN108348473B (zh) 2021-06-18
PH12018501001A1 (en) 2018-12-17
WO2017083304A1 (en) 2017-05-18
SV2018005682A (es) 2018-08-15
AU2020200995B9 (en) 2022-04-28
AU2016354007A8 (en) 2018-06-14
KR20240095320A (ko) 2024-06-25
TWI737647B (zh) 2021-09-01
AU2016354007B2 (en) 2019-11-14
NZ741957A (en) 2019-04-26
KR20200106222A (ko) 2020-09-11
SI3346995T1 (sl) 2019-11-29
CA2948021C (en) 2024-06-18
US20170189337A1 (en) 2017-07-06
EP3346995A1 (en) 2018-07-18
AU2016354007C9 (en) 2020-10-01
CL2018001199A1 (es) 2018-09-28
KR102153996B1 (ko) 2020-09-09
EA201890654A1 (ru) 2018-10-31
SG11201802983TA (en) 2018-05-30
PT3346995T (pt) 2019-11-22

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
SI3346995T1 (sl) Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
HUE045137T2 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
HUE059694T2 (hu) Készítmény rák kezelésére
DK3360508T3 (da) Hjælpeanordning til dental behandling
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
DK3068392T5 (da) Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
PT3286166T (pt) Inibidores de replicação do vírus da imunodeficiência humana
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
HUE049413T2 (hu) Nazális porkészítmény hipoglikémia kezelésére
DK3116491T3 (da) Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
IL257355B (en) Selection of patients for combination therapy
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére